Andrew L. Kung

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias

  Cancer Discovery · 2026-04-30

• Abstract 7801: Preclinical efficacy of DLL3 targeted CAR T cells in neuroblastoma

  Cancer Research · 2026-04-03

• Abstract 1157: Preclinical evaluation of PEG-[SN22]4 (PEEL-224), a multivalent polymeric camptothecin prodrug, in pediatric solid tumor patient-derived xenograft models

  Cancer Research · 2026-04-03

• Abstract 1540: Development of EPHA2 car t cell therapy for solid tumors

  Cancer Research · 2026-04-03

• Abstract 4958: Spatial transcriptomic profiling reveals heterogeneity in desmoplastic small round cell tumor

  Cancer Research · 2026-04-03

• Abstract 7812: Preclinical evaluation of a dnTGFβR-armored GPC3 CAR-T (AZD5851) in pediatric solid tumor PDX models - A report from the Pediatric Preclinical <i>In Vivo</i> Testing (PIVOT) Consortium

  Cancer Research · 2026-04-03

• Balancing Rigor and Urgency: The Development of Trastuzumab Deruxtecan in Rare and Ultra-Rare Sarcomas

  JCO oncology advances. · 2026-04-01

• Single-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies in <i>MYOD1</i> -mutant rhabdomyosarcoma

  Science Advances · 2026-02-27 · 1 citations

• SMARCAL1 is a candidate therapeutic target for ALT-positive tumors

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-02-16 · 2 citations

• Low α-Diversity and Enterococcus Faecium Domination Are Associated with Increased Mortality in Pediatric Allogeneic HCT Recipients.

  Transplantation and Cellular Therapy · 2026-02-01

• Data from Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression

  2026-01-02

• Figure S2 from Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression

  2026-01-02

• Figure S1 from Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression

  2026-01-02

• Supplementary Table 1 from Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression

  2026-01-02

• Trastuzumab Deruxtecan Is Active in Desmoplastic Small Round Cell Tumor

  JCO oncology advances. · 2026-01-01 · 1 citations

• Table S7 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S8 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S3 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Key Resources Table from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S1 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11